Ackley J et al. Keeping myeloma in check: The past, present and future of immunotherapy in multiple myeloma. Cancers (Basel) 2021;13(19):4787. Abstract
Anderson KC et al. Minimal residual disease in myeloma: Application for clinical care and new drug registration. Clin Cancer Res 2021;27(19):5195-212. Abstract
Davies FE et al. Perspectives on the risk-stratified treatment of multiple myeloma. Blood Cancer Discov 2022;3(4):273-84. Abstract
Dhakal B et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma. Transplant Cell Ther 2022;28(6):284-93. Abstract
Dimopoulos MA et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): An open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022;9(6):e403-14. Abstract
Dimopoulos MA et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial. J Clin Oncol 2020;38(34):4030-41. Abstract
Dimopoulos MA et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393(10168):253-64. Abstract
Dimopoulos MA et al. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2022;22(7):460-73. Abstract
D’Souza A, Lonial S. What the Princess Bride teaches us about outcomes in multiple myeloma. J Clin Oncol 2021;39(22):2423-5. Abstract
Einsele H et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A. ASCO 2022;Abstract 8020.
Facon T et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(11):1582-96. Abstract
Goldschmidt H et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: The phase III GMMG-HD7 trial. ASH 2021;Abstract 463.
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Gupta VA et al. Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood Cancer J 2022;12(8):115. Abstract
Gupta VA et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 2021;137(26):3604-15. Abstract
Jakubowiak A et al. Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 2021;21(10):701-10. Abstract
Joseph NS et al. Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life. Transplant Cell Ther 2022;28(2):75.e1-7. Abstract
Joseph NS et al. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol 2021;13:169-80. Abstract
Kumar SK et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21(10):1317-30. Abstract
Kumar SK et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASH 2021;Abstract 84.
Lesokhin AM et al. Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). ASCO 2022;Abstract 8006.
Lonial S et al. Characterization of ocular adverse events in patients receiving belantamab mafodotin for ≥12 months: Post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma. EHA 2021;Abstract EP1026.
Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up in pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract
Lonial S et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11(5):103. Abstract
Lonial S et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. ASCO 2022;Abstract 8019.
Maples KT et al. Antibody treatment in multiple myeloma. Clin Adv Hematol Oncol 2021;19(3):166-74. Abstract
Maples KT et al. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. Am J Hematol 2021;96(3):E68-71. Abstract
McCarthy PL et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. J Clin Oncol 2017;35(29):3279-89. Abstract
Minnema MC et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Updated results from the MonumenTAL-1. ASCO 2022;Abstract 8015.
Mo CC et al. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol 2021;14(8):697-706. Abstract
Moreau P et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): An open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(10):1378-90. Abstract
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;386(6):495-505. Abstract
Munshi PN et al. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer 2021;127(22):4233-9. Abstract
Munshi N et al. Trial-in-progress: Phase II study of PHE885, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in adults with relapsed and/or refractory multiple myeloma. EHA 2022;Abstract PB1983.
Nooka AK et al. “I took the road less traveled, and that has made all the difference”: Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. Cancer 2021;127(22):4133-6. Abstract
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from the MajesTEC-1. ASCO 2022;Abstract 8007.
Patel K, Lonial S. When an embarrassment of riches isn’t enough. Nat Rev Clin Oncol 2022;19(10):617-8. Abstract
Popat R et al. Can patient-reported ocular symptoms guide dose modifications in patients with relapsed/refractory multiple myeloma receiving belantamab mafodotin? ASH 2021;Abstract 2746.
Raje NS et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group. Lancet Haematol 2022;9(2):e143-61. Abstract
Rajkumar SV et al. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J 2022;12(9):129. Abstract
Richardson PG et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2021;39(22):2430-42. Abstract
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. ASCO 2022;Abstract LBA4.
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Sborov DW et al. Daratumumab (DARA) + lenalidomide, bortezomib, dexamethasone (RVd) ± in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Final analysis of GRIFFIN. IMS 2022;Abstract OAB-057.
Terpos E et al. Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology. EHA 2022;Abstract S178.
Touzeau C et al. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04. ASCO 2022;Abstract 8002.
Trudel S et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study. ASH 2021;Abstract 157.
Usmani SZ et al. DREAMM-9: Phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. EHA 2022;Abstract P942.
van de Donk NWCJ et al. Biological correlative analyses an updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. ASCO 2022;Abstract 8029.
van de Donk NWCJ et al. Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: Updated phase 1b results for talquetamab (a GPRC5D x CD3 bispecific antibody) in combination with daratumumab. EHA 2022;Abstract S183.
Vo JN et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 2022;13(1):3750. Abstract